Showing results (61-70 of 648) with videos related to

Sort By:
Pageof 65
Blood|July 27, 2001
STAT3 is constitutively activated in Hodgkin cell linesD Kube, U Holtick, M Vockerodt, et al.
Cancer Research|July 15, 1991
Patterns of DNA methylation in selected human genes in different Hodgkin's lymphoma and leukemia cell lines and in normal human lymphocytesS Achten, A Behn-Krappa, M Jücker, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 26, 1998
Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissuesJ Irsch, S Nitsch, M L Hansmann, et al.
Cancer Research|May 1, 1997
Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cellsH Bohlen, O Manzke, S Titzer, et al.
Oncogene|May 1, 1992
Expression of truncated transcripts of the proto-oncogene c-fps/fes in human lymphoma and lymphoid leukemia cell linesM Jücker, A J Roebroek, J Mautner, et al.
Leukemia & Lymphoma|March 18, 2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Leukemia & Lymphoma|March 18, 2000
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphomaA Josting, M Reiser, P D Wickramanayake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patientsP Staib, B Lathan, S Knöppel-Schwark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1995
Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG)V Diehl, M Loeffler, M Pfreundschuh, et al.
American Journal of Physiology. Renal Physiology|February 15, 2008
MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathyG H Tesch
Pageof 65